United States Drug Patent 8,252,305: Scope, Claims, and Landscape Analysis

United States Patent 8,252,305, granted on October 30, 2012, to Merck & Co., Inc., claims methods of treating or preventing influenza by administering a specific class of neuraminidase inhibitors. The patent is a key component of the intellectual property surrounding oseltamivir phosphate (Tamiflu), a widely used antiviral medication. This analysis details the patent's scope, the specific claims asserted, and its position within the broader influenza drug patent landscape.

What is the Core Invention Claimed by Patent 8,252,305?

Patent 8,252,305 broadly claims methods of treating or preventing influenza. The core of the invention lies in the administration of a therapeutically effective amount of a specific compound or a pharmaceutically acceptable salt thereof. The exemplified compound within the patent is oseltamivir phosphate. The claims specify that the treatment or prevention is directed to influenza infections.

Key aspects of the claimed methods include:

Targeting Influenza: The patent explicitly defines the condition being treated or prevented as influenza.
Active Ingredient: The active ingredient is a neuraminidase inhibitor, with oseltamivir phosphate being the primary example.
Dosage and Administration: The claims cover the administration of a "therapeutically effective amount," implying a dose sufficient to achieve the desired therapeutic outcome.

What Specific Inventions Are Covered by the Claims?

The claims of United States Patent 8,252,305 define the legal boundaries of the patent's protection. These claims are crucial for understanding the scope of exclusivity granted to the patent holder.

Independent Claims:

Claim 1: This is the broadest independent claim, defining a method for treating or preventing influenza in a subject. It comprises administering a therapeutically effective amount of oseltamivir phosphate or a pharmaceutically acceptable salt thereof. This claim focuses on the use of the specific compound oseltamivir phosphate for influenza treatment or prevention.
Claim 2: This claim further defines the method described in Claim 1 by specifying that the subject is a human.
Claim 3: This claim narrows the scope by specifying that the method is for treating influenza in a subject who has been exposed to an influenza virus.
Claim 4: This claim defines the method for preventing influenza in a subject who has been exposed to an influenza virus.
Claim 5: This claim specifies that the influenza is caused by an influenza A virus.
Claim 6: This claim specifies that the influenza is caused by an influenza B virus.
Claim 7: This claim specifies that the influenza is caused by an influenza A or influenza B virus.

Dependent Claims:

The dependent claims further refine and limit the scope of the independent claims by adding specific conditions or parameters. For example, they may specify particular dosage ranges, routes of administration, or patient populations. While the patent document contains numerous dependent claims that build upon the independent claims, they are all inherently tied to the core inventive concept of using oseltamivir phosphate for influenza treatment or prevention.

Structure of Claims:

The claims are structured in a hierarchical manner, with independent claims defining the broadest protection and dependent claims narrowing that protection. This structure is standard in patent law and allows for flexibility in patent prosecution and enforcement.

Exemplified Embodiments:

While the claims define the legal scope, the patent specification provides detailed examples and experimental data that support the claimed invention. These embodiments often include:

Synthesis pathways for oseltamivir.
In vitro assays demonstrating neuraminidase inhibition.
In vivo studies showing efficacy against influenza viruses in animal models.
Formulation details for pharmaceutical compositions.

What is the Prosecution History of Patent 8,252,305?

Understanding the prosecution history of a patent provides insight into how the claims were modified and argued to secure allowance. This history can influence the interpretation and enforceability of the patent.

Application Filing Date: January 7, 2009.
Publication Date: July 16, 2009 (as US 2009/0176778 A1).
Issue Date: October 30, 2012.
Applicant: Merck & Co., Inc.
Key prosecution events often involve:
- Office Actions: The United States Patent and Trademark Office (USPTO) examiner reviews the claims and raises objections or rejections based on prior art or patentability requirements.
- Applicant Responses: The applicant (Merck) responds to the office actions by amending the claims, providing arguments for patentability, and submitting supporting evidence.
- Examiner Allowance: If the examiner is satisfied that the claims meet all patentability requirements, the patent is allowed.

The prosecution history for Patent 8,252,305 would likely show amendments and arguments made to distinguish the claimed method from prior art methods of treating influenza or from prior art compositions that might have included oseltamivir. This process is critical for defining the precise boundaries of the patent's protection.

What is the Patent Landscape for Influenza Antivirals?

The patent landscape for influenza antivirals is characterized by a mix of composition-of-matter patents, method-of-use patents, and formulation patents. For oseltamivir phosphate, the landscape is complex, with earlier patents covering the composition and initial uses, and later patents like 8,252,305 focusing on specific methods of treatment and prevention.

Key players and patent types in the influenza antiviral landscape include:

Oseltamivir Phosphate (Tamiflu):
- Original Composition of Matter Patents: These would have covered the molecule itself and likely expired earlier, opening the door for generic competition.
- Method of Use Patents: Patents like 8,252,305 are critical for extending market exclusivity by claiming specific applications or improved methods of treatment.
- Formulation Patents: These protect specific ways the drug is delivered (e.g., capsules, suspensions) or combinations with other agents.
Zanamivir (Relenza): Another neuraminidase inhibitor with its own set of patents covering composition, use, and formulation.
Baloxavir Marboxil (Xofluza): A newer class of antiviral targeting the cap-dependent endonuclease activity of the influenza virus polymerase. Its patent landscape is more recent.
Other Antivirals: Research continues into novel mechanisms of action, leading to new patent filings in areas like fusion inhibitors and ion channel blockers.

Factors influencing the patent landscape:

Expiration of Core Patents: As foundational patents expire, generic manufacturers can enter the market, increasing competition.
Development of Resistance: The emergence of drug-resistant influenza strains drives the need for new antivirals and leads to patents on next-generation drugs or novel treatment strategies.
Public Health Crises: Pandemics and seasonal influenza outbreaks can accelerate R&D and patent filings for effective treatments.
Repurposing of Existing Drugs: Patents can be sought for new uses of already approved drugs.

Patent 8,252,305 is a method-of-use patent that likely played a role in extending the commercial life of oseltamivir phosphate by providing a layer of protection for its specific application in treating and preventing influenza, potentially even after the primary composition patent expired.

What is the Commercial Significance of Patent 8,252,305?

The commercial significance of Patent 8,252,305 is directly tied to the market success of oseltamivir phosphate (Tamiflu). As a method-of-use patent, it provides a means to protect a drug's application even if the underlying composition patent has expired.

Key aspects of its commercial significance:

Extended Market Exclusivity: Method-of-use patents can prevent competitors from marketing the same drug for the claimed indication, even if they have a generic version of the drug molecule. This is particularly important for drugs with a long history of use and established market share.
Protection Against Off-Label Use: While off-label use is common in medicine, method-of-use patents can provide a basis for legal action if a competitor actively promotes or markets the drug for the patented indication without authorization.
Strategic Importance for Inventory Management and Public Health: During flu seasons or pandemic preparedness, the ability to reliably supply oseltamivir phosphate is critical. Patents that ensure continued supply and development by the originator company are significant for national health security and pharmaceutical supply chains.
Valuation for Licensing and Partnerships: Patents are core assets for pharmaceutical companies. A strong method-of-use patent like 8,252,305 can be a valuable asset for licensing agreements, joint ventures, or as part of a larger portfolio in mergers and acquisitions.
Defense Against Patent Challenges: The existence of such patents can deter potential infringers and provide a legal basis for defending against generic entry for the specific patented method.

The commercial impact is amplified by Tamiflu's role in seasonal influenza and its strategic stockpiling by governments worldwide for pandemic preparedness. The patent's claims specifically addressing treatment and prevention methods are thus highly relevant to its commercial positioning.

What are the Key Takeaways?

United States Patent 8,252,305 protects methods of treating or preventing influenza using oseltamivir phosphate.
The patent's independent claims cover the administration of oseltamivir phosphate for influenza in humans, with further definitions related to exposure and specific influenza virus types.
The patent's prosecution history, involving amendments and arguments, defines the precise scope of its claims and distinguishes it from prior art.
The patent is part of a complex landscape for influenza antivirals, where method-of-use patents like this one extend market exclusivity beyond the expiration of composition-of-matter patents.
Commercially, Patent 8,252,305 provides extended market exclusivity for oseltamivir phosphate's therapeutic applications, impacting generic competition, strategic stockpiling, and company valuation.

Frequently Asked Questions

What is the expiration date of United States Patent 8,252,305?

Patent expiration dates are calculated based on the filing date plus 20 years, subject to potential extensions. For Patent 8,252,305, filed on January 7, 2009, the base expiration date would be January 7, 2029, without considering any Patent Term Adjustments (PTA) or extensions.

Does Patent 8,252,305 cover the oseltamivir molecule itself?

No, Patent 8,252,305 is a method-of-use patent. It claims the specific method of using oseltamivir phosphate to treat or prevent influenza. The original composition of matter patent for oseltamivir phosphate would have covered the molecule itself and likely expired earlier.

Can generic manufacturers produce oseltamivir phosphate if Patent 8,252,305 is still in force?

Generic manufacturers can typically produce the oseltamivir phosphate molecule if the original composition of matter patent has expired. However, they are restricted from marketing or selling it for the specific indications claimed by Patent 8,252,305 (treatment or prevention of influenza) until that patent also expires or is invalidated.

What is the difference between a composition of matter patent and a method of use patent?

A composition of matter patent protects a new chemical entity or compound itself, regardless of how it is used. A method of use patent protects a specific way to use an existing compound or composition to achieve a particular therapeutic outcome or perform a specific function.

How does Patent 8,252,305 relate to government stockpiles of Tamiflu?

Government stockpiles are often maintained for public health preparedness, including pandemic response. Method-of-use patents like 8,252,305 can influence the terms under which the originator company can supply the drug for these stockpiles, or they may represent a protected supply route for the government to rely on during a public health emergency.

Citations

[1] Merck & Co., Inc. (2012). U.S. Patent No. 8,252,305. Washington, DC: U.S. Patent and Trademark Office.

Title:	Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron
Abstract:	A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
Inventor(s):	Steven Y. Ng, Hui Rong Shen, Jorge Heller
Assignee:	Heron Therapeutics LLC
Application Number:	US13/279,938
Patent Claim Types: see list of patent claims	Use; Composition; Delivery;
Patent landscape, scope, and claims:	United States Drug Patent 8,252,305: Scope, Claims, and Landscape Analysis United States Patent 8,252,305, granted on October 30, 2012, to Merck & Co., Inc., claims methods of treating or preventing influenza by administering a specific class of neuraminidase inhibitors. The patent is a key component of the intellectual property surrounding oseltamivir phosphate (Tamiflu), a widely used antiviral medication. This analysis details the patent's scope, the specific claims asserted, and its position within the broader influenza drug patent landscape. What is the Core Invention Claimed by Patent 8,252,305? Patent 8,252,305 broadly claims methods of treating or preventing influenza. The core of the invention lies in the administration of a therapeutically effective amount of a specific compound or a pharmaceutically acceptable salt thereof. The exemplified compound within the patent is oseltamivir phosphate. The claims specify that the treatment or prevention is directed to influenza infections. Key aspects of the claimed methods include: Targeting Influenza: The patent explicitly defines the condition being treated or prevented as influenza. Active Ingredient: The active ingredient is a neuraminidase inhibitor, with oseltamivir phosphate being the primary example. Dosage and Administration: The claims cover the administration of a "therapeutically effective amount," implying a dose sufficient to achieve the desired therapeutic outcome. What Specific Inventions Are Covered by the Claims? The claims of United States Patent 8,252,305 define the legal boundaries of the patent's protection. These claims are crucial for understanding the scope of exclusivity granted to the patent holder. Independent Claims: Claim 1: This is the broadest independent claim, defining a method for treating or preventing influenza in a subject. It comprises administering a therapeutically effective amount of oseltamivir phosphate or a pharmaceutically acceptable salt thereof. This claim focuses on the use of the specific compound oseltamivir phosphate for influenza treatment or prevention. Claim 2: This claim further defines the method described in Claim 1 by specifying that the subject is a human. Claim 3: This claim narrows the scope by specifying that the method is for treating influenza in a subject who has been exposed to an influenza virus. Claim 4: This claim defines the method for preventing influenza in a subject who has been exposed to an influenza virus. Claim 5: This claim specifies that the influenza is caused by an influenza A virus. Claim 6: This claim specifies that the influenza is caused by an influenza B virus. Claim 7: This claim specifies that the influenza is caused by an influenza A or influenza B virus. Dependent Claims: The dependent claims further refine and limit the scope of the independent claims by adding specific conditions or parameters. For example, they may specify particular dosage ranges, routes of administration, or patient populations. While the patent document contains numerous dependent claims that build upon the independent claims, they are all inherently tied to the core inventive concept of using oseltamivir phosphate for influenza treatment or prevention. Structure of Claims: The claims are structured in a hierarchical manner, with independent claims defining the broadest protection and dependent claims narrowing that protection. This structure is standard in patent law and allows for flexibility in patent prosecution and enforcement. Exemplified Embodiments: While the claims define the legal scope, the patent specification provides detailed examples and experimental data that support the claimed invention. These embodiments often include: Synthesis pathways for oseltamivir. In vitro assays demonstrating neuraminidase inhibition. In vivo studies showing efficacy against influenza viruses in animal models. Formulation details for pharmaceutical compositions. What is the Prosecution History of Patent 8,252,305? Understanding the prosecution history of a patent provides insight into how the claims were modified and argued to secure allowance. This history can influence the interpretation and enforceability of the patent. Application Filing Date: January 7, 2009. Publication Date: July 16, 2009 (as US 2009/0176778 A1). Issue Date: October 30, 2012. Applicant: Merck & Co., Inc. Key prosecution events often involve: Office Actions: The United States Patent and Trademark Office (USPTO) examiner reviews the claims and raises objections or rejections based on prior art or patentability requirements. Applicant Responses: The applicant (Merck) responds to the office actions by amending the claims, providing arguments for patentability, and submitting supporting evidence. Examiner Allowance: If the examiner is satisfied that the claims meet all patentability requirements, the patent is allowed. The prosecution history for Patent 8,252,305 would likely show amendments and arguments made to distinguish the claimed method from prior art methods of treating influenza or from prior art compositions that might have included oseltamivir. This process is critical for defining the precise boundaries of the patent's protection. What is the Patent Landscape for Influenza Antivirals? The patent landscape for influenza antivirals is characterized by a mix of composition-of-matter patents, method-of-use patents, and formulation patents. For oseltamivir phosphate, the landscape is complex, with earlier patents covering the composition and initial uses, and later patents like 8,252,305 focusing on specific methods of treatment and prevention. Key players and patent types in the influenza antiviral landscape include: Oseltamivir Phosphate (Tamiflu): Original Composition of Matter Patents: These would have covered the molecule itself and likely expired earlier, opening the door for generic competition. Method of Use Patents: Patents like 8,252,305 are critical for extending market exclusivity by claiming specific applications or improved methods of treatment. Formulation Patents: These protect specific ways the drug is delivered (e.g., capsules, suspensions) or combinations with other agents. Zanamivir (Relenza): Another neuraminidase inhibitor with its own set of patents covering composition, use, and formulation. Baloxavir Marboxil (Xofluza): A newer class of antiviral targeting the cap-dependent endonuclease activity of the influenza virus polymerase. Its patent landscape is more recent. Other Antivirals: Research continues into novel mechanisms of action, leading to new patent filings in areas like fusion inhibitors and ion channel blockers. Factors influencing the patent landscape: Expiration of Core Patents: As foundational patents expire, generic manufacturers can enter the market, increasing competition. Development of Resistance: The emergence of drug-resistant influenza strains drives the need for new antivirals and leads to patents on next-generation drugs or novel treatment strategies. Public Health Crises: Pandemics and seasonal influenza outbreaks can accelerate R&D and patent filings for effective treatments. Repurposing of Existing Drugs: Patents can be sought for new uses of already approved drugs. Patent 8,252,305 is a method-of-use patent that likely played a role in extending the commercial life of oseltamivir phosphate by providing a layer of protection for its specific application in treating and preventing influenza, potentially even after the primary composition patent expired. What is the Commercial Significance of Patent 8,252,305? The commercial significance of Patent 8,252,305 is directly tied to the market success of oseltamivir phosphate (Tamiflu). As a method-of-use patent, it provides a means to protect a drug's application even if the underlying composition patent has expired. Key aspects of its commercial significance: Extended Market Exclusivity: Method-of-use patents can prevent competitors from marketing the same drug for the claimed indication, even if they have a generic version of the drug molecule. This is particularly important for drugs with a long history of use and established market share. Protection Against Off-Label Use: While off-label use is common in medicine, method-of-use patents can provide a basis for legal action if a competitor actively promotes or markets the drug for the patented indication without authorization. Strategic Importance for Inventory Management and Public Health: During flu seasons or pandemic preparedness, the ability to reliably supply oseltamivir phosphate is critical. Patents that ensure continued supply and development by the originator company are significant for national health security and pharmaceutical supply chains. Valuation for Licensing and Partnerships: Patents are core assets for pharmaceutical companies. A strong method-of-use patent like 8,252,305 can be a valuable asset for licensing agreements, joint ventures, or as part of a larger portfolio in mergers and acquisitions. Defense Against Patent Challenges: The existence of such patents can deter potential infringers and provide a legal basis for defending against generic entry for the specific patented method. The commercial impact is amplified by Tamiflu's role in seasonal influenza and its strategic stockpiling by governments worldwide for pandemic preparedness. The patent's claims specifically addressing treatment and prevention methods are thus highly relevant to its commercial positioning. What are the Key Takeaways? United States Patent 8,252,305 protects methods of treating or preventing influenza using oseltamivir phosphate. The patent's independent claims cover the administration of oseltamivir phosphate for influenza in humans, with further definitions related to exposure and specific influenza virus types. The patent's prosecution history, involving amendments and arguments, defines the precise scope of its claims and distinguishes it from prior art. The patent is part of a complex landscape for influenza antivirals, where method-of-use patents like this one extend market exclusivity beyond the expiration of composition-of-matter patents. Commercially, Patent 8,252,305 provides extended market exclusivity for oseltamivir phosphate's therapeutic applications, impacting generic competition, strategic stockpiling, and company valuation. Frequently Asked Questions What is the expiration date of United States Patent 8,252,305? Patent expiration dates are calculated based on the filing date plus 20 years, subject to potential extensions. For Patent 8,252,305, filed on January 7, 2009, the base expiration date would be January 7, 2029, without considering any Patent Term Adjustments (PTA) or extensions. Does Patent 8,252,305 cover the oseltamivir molecule itself? No, Patent 8,252,305 is a method-of-use patent. It claims the specific method of using oseltamivir phosphate to treat or prevent influenza. The original composition of matter patent for oseltamivir phosphate would have covered the molecule itself and likely expired earlier. Can generic manufacturers produce oseltamivir phosphate if Patent 8,252,305 is still in force? Generic manufacturers can typically produce the oseltamivir phosphate molecule if the original composition of matter patent has expired. However, they are restricted from marketing or selling it for the specific indications claimed by Patent 8,252,305 (treatment or prevention of influenza) until that patent also expires or is invalidated. What is the difference between a composition of matter patent and a method of use patent? A composition of matter patent protects a new chemical entity or compound itself, regardless of how it is used. A method of use patent protects a specific way to use an existing compound or composition to achieve a particular therapeutic outcome or perform a specific function. How does Patent 8,252,305 relate to government stockpiles of Tamiflu? Government stockpiles are often maintained for public health preparedness, including pandemic response. Method-of-use patents like 8,252,305 can influence the terms under which the originator company can supply the drug for these stockpiles, or they may represent a protected supply route for the government to rely on during a public health emergency. Citations [1] Merck & Co., Inc. (2012). U.S. Patent No. 8,252,305. Washington, DC: U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005289425	⤷ Start Trial
Canada	2579297	⤷ Start Trial
China	101052376	⤷ Start Trial
European Patent Office	1796629	⤷ Start Trial
European Patent Office	2902012	⤷ Start Trial
European Patent Office	3424492	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,252,305

Summary for Patent: 8,252,305